Billeaud Capital Management Inc. held its position in Becton, Dickinson and Company (NYSE:BDX) during the second quarter, Holdings Channel reports. The firm owned 2,359 shares of the medical instruments supplier’s stock at the end of the second quarter. Becton, Dickinson and comprises 0.3% of Billeaud Capital Management Inc.’s portfolio, making the stock its 24th largest position. Billeaud Capital Management Inc.’s holdings in Becton, Dickinson and were worth $460,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of the company. Guardian Life Insurance Co. of America boosted its stake in shares of Becton, Dickinson and by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 819 shares of the medical instruments supplier’s stock worth $150,000 after buying an additional 6 shares during the last quarter. Wellington Shields & Co. LLC boosted its stake in shares of Becton, Dickinson and by 0.3% in the second quarter. Wellington Shields & Co. LLC now owns 2,541 shares of the medical instruments supplier’s stock worth $496,000 after buying an additional 7 shares during the last quarter. Parkside Financial Bank & Trust boosted its stake in shares of Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the last quarter. Northstar Group Inc. boosted its stake in shares of Becton, Dickinson and by 0.3% in the second quarter. Northstar Group Inc. now owns 2,994 shares of the medical instruments supplier’s stock worth $584,000 after buying an additional 9 shares during the last quarter. Finally, Capital Investment Advisors LLC boosted its stake in shares of Becton, Dickinson and by 0.7% in the first quarter. Capital Investment Advisors LLC now owns 2,412 shares of the medical instruments supplier’s stock worth $442,000 after buying an additional 17 shares during the last quarter. 75.57% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company (NYSE BDX) traded down 0.22% during midday trading on Wednesday, hitting $201.04. 492,319 shares of the company’s stock traded hands. The company has a 50 day moving average of $199.29 and a 200-day moving average of $188.36. Becton, Dickinson and Company has a 52 week low of $161.29 and a 52 week high of $206.63. The company has a market capitalization of $45.75 billion, a PE ratio of 58.22 and a beta of 1.05.

Becton, Dickinson and (NYSE:BDX) last posted its earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The firm had revenue of $3.04 billion during the quarter, compared to analyst estimates of $3.06 billion. During the same period in the previous year, the company earned $2.35 EPS. The company’s revenue for the quarter was down 5.1% on a year-over-year basis. Equities research analysts predict that Becton, Dickinson and Company will post $9.46 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, September 29th. Investors of record on Friday, September 8th will be issued a $0.73 dividend. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a yield of 1.45%. Becton, Dickinson and’s dividend payout ratio (DPR) is currently 83.43%.

TRADEMARK VIOLATION WARNING: “Billeaud Capital Management Inc. Has $460,000 Stake in Becton, Dickinson and Company (BDX)” was first published by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.watchlistnews.com/billeaud-capital-management-inc-has-460000-stake-in-becton-dickinson-and-company-bdx/1496102.html.

A number of brokerages recently commented on BDX. Barclays PLC reissued an “equal weight” rating and issued a $210.00 price objective (up from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. BidaskClub cut shares of Becton, Dickinson and from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Zacks Investment Research cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Thursday, May 4th. Stifel Nicolaus reissued a “buy” rating on shares of Becton, Dickinson and in a research note on Wednesday, August 9th. Finally, Evercore ISI raised shares of Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $186.00 to $200.00 in a research note on Monday, April 24th. One research analyst has rated the stock with a sell rating, five have given a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $195.79.

In related news, insider Nabil Shabshab sold 6,149 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $201.76, for a total value of $1,240,622.24. Following the completion of the sale, the insider now directly owns 15,648 shares in the company, valued at approximately $3,157,140.48. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Ribo Alberto Mas sold 7,463 shares of the business’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $201.41, for a total value of $1,503,122.83. Following the completion of the sale, the executive vice president now owns 29,323 shares of the company’s stock, valued at $5,905,945.43. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 57,631 shares of company stock valued at $11,112,178. Corporate insiders own 1.40% of the company’s stock.

About Becton, Dickinson and

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with Analyst Ratings Network's FREE daily email newsletter.